Sep 25 & Oct 2, 2026

Conference Agenda

  Download Agenda PDF
Sep 25 Oct 2
Agenda : Friday, September 25, 2026
Time Topic Speaker(s)
10:00 AM Welcome & Introduction
10:05 AM Beyond Adolescence: Broadening HPV Vaccination Across Diverse Patient Populations

At the conclusion of this activity participants will be able to:

  • Describe the prevalence and impact of HPV infection and its associated cancers across diverse patient populations
  • Explain the rationale for HPV vaccination in adolescents, including the role of publicly funded programs and current uptake trends in Canada
  • Explain the rationale for HPV vaccination beyond adolescence, including benefits for adults, men, and individuals in monogamous relationships
  • Apply current HPV vaccination recommendations and interprofessional strategies to build confidence and improve uptake across care settings, including cervical cancer screening visits
 Dr. Shannon Salvador & Dr. Sheila Wijayasinghe
11:15 AM Integrating Sleep into Obesity Care: Practical Strategies for Primary Care

At the conclusion of this activity participants will be able to:

  • Describe the relationship between sleep health and obesity
  • Examine how sleep fits into the overall patient journey in obesity management.
  • Apply practical strategies for integrating sleep considerations into comprehensive obesity
 Dr. Jonathan Gabor
12:15 PM Virtual Exhibit Hall & Refreshment Break
01:00 PM Putting CGM to Work: A Guide for Canadian Clinicians

At the conclusion of this activity participants will be able to:

  • Describe the current Diabetes Canada guideline recommendations for CGM use in individuals with T1D and T2D
  • Identify appropriate candidates for CGM across the spectrum of diabetes types and therapies
  • Interpret CGM data to guide individualized pharmacotherapy adjustments.
  • Discuss the practical aspects of CGM implementation with patients and the interprofessional team
 Dr. Alex Abitbol & Dr. Daniel Ngui
02:10 PM Advanced Topical Therapy Management Options in Atopic Dermatitis

At the conclusion of this activity participants will be able to:

  • Identify the key clinical features and differential diagnoses of common chronic inflammatory dermatoses - including AD, plaque psoriasis (PsO), and seborrheic dermatitis (seb derm) - in adult and pediatric primary-care patients.
  • Evaluate the benefits and limitations of current topical treatment options, including the clinical impact of inappropriate long-term topical corticosteroid use and growing concerns about corticophobia.
  • Discuss the clinical impact of formulation considerations in the vehicle aspect of topical agents, particularly with the atopic dermatitis patient in mind
  • Assess the evidence from pivotal clinical trials on recently approved advanced non-steroidal targeted topical therapies in AD across adult and pediatric patients.
 Dr. Farheen Mussani
03:20 PM Prevention and Early Detection to Halt the Slide: Chronic Kidney Disease (CKD) in Diabetes Guideline Updates

At the conclusion of this activity participants will be able to:

  • Identify screening recommendations for CKD in people with diabetes
  • Describe health behaviours and new therapies to prevent onset and progression of diabetic nephropathy toward end stage kidney disease
  • Integrate new Diabetes Canada recommendations into clinical practice
 Dr. Sheldon Tobe
04:30 PM Reframing Insomnia Management: Evidence-Based Strategies and Clinical Insights for Primary Care

At the conclusion of this activity participants will be able to:

  • Apply evidence-based assessment tools to evaluate patients with insomnia.
  • Analyze the benefits and limitations of non-pharmacological interventions as first-linetherapy.
  • Evaluate pharmacological treatment options based on patient-specific factors.
  • Create safe and effective transition strategies between different classes of insomnia medications, including dual orexin receptor antagonists (DORAs).
  • Formulate comprehensive management plans integrating pharmacological and non-pharmacological interventions.
 Dr. Serge Lessard
05:30 PM Closing Remarks
Agenda : Friday, October 02, 2026
Time Topic Speaker(s)
10:00 AM Welcome & Introduction
10:05 AM Aldosterone Unleashed: Cracking Resistant Hypertension

At the conclusion of this activity participants will be able to:

  • Explain how aldosterone contributes to uncontrolled and resistant hypertension
  • Assess clinical evidence for established and novel aldosterone-targeted therapies
  • Implement streamlined approaches to optimize hypertension management
 Dr. Peter Lin
11:15 AM Faster Testing for Slower Decline: How to improve early detection and referrals in Alzheimer’s disease and why it matters

At the conclusion of this activity participants will be able to:

  • Recognize cognitive, behavioural, and functional changes that warrant a dementia work-up
  • Describe the value of diagnosing Alzheimer’s disease as early as possible
  • Answer patients’ questions about blood-based biomarkers and disease-modifying therapy (DMT)
  • Identify patients who should be fast-tracked for referral due to urgent concerns or eligibility for DMT
 Dr. Sharon Cohen
12:15 PM Virtual Exhibit Hall & Refreshment Break
01:00 PM The First Years Matter: Shaping the Trajectory of T2D Through Early Action

At the conclusion of this activity participants will be able to:

  • Describe the importance of early treatment optimization in altering the long-term trajectory of T2D.
  • Identify patient factors that influence early treatment decisions in T2D.
  • Apply current evidence and guideline recommendations to individualize treatment strategies early in the T2D disease course.
  • Evaluate the evolving role of oral and injectable incretin-based therapies in the T2D continuum.
 Dr. Jeremy Gilbert
02:10 PM Closing the Prevention Gap in Adult Pneumococcal Disease: Evolving Evidence for Primary Care and Pharmacy Practice

At the conclusion of this activity participants will be able to:

  • Describe the burden of adult pneumococcal disease in Canada, including the role of the aging immune system
  • Recognize opportunities for primary care physicians and pharmacists to collaborate to improve disease prevention in adults at risk for invasive pneumococcal disease (IPD)
  • Apply current Canadian pneumococcal vaccination recommendations to adult patient care
 Dr. Alan Kaplan & Sherilyn Houle
03:20 PM The Role of the Primary Care Physician in the Multi-Disciplinary Management of Dyslipidemia in Patients with ASCVD

At the conclusion of this activity participants will be able to:

  • Identify patients who would derive the largest benefit from additional therapy beyond statins to reduce CV risk
  • Apply the evidence from clinical trials, guideline recommendations and real-world data for PCSK9 inhibitor therapy to routine clinical decision making for ASCVD patients
  • Recognize the role of the primary care physician through case-based learning in achieving guideline-recommended LDL-C threshold recommendations in ASCVD patients, including those at highest-risk, to reduce recurrent events
 Dr. Richard Choi
04:30 PM Applying Lipid Guidelines in Primary Care: Challenges and Opportunities

At the conclusion of this activity participants will be able to:

  • Identify challenges in applying lipid guidelines in primary care
  • Summarize new evidence that may influence the future evolution of lipid guidelines
  • Develop strategies incorporating recent international guidelines for best practices in lipid management
 Dr. Milan Gupta & Dr. Robert Hegele
05:30 PM Closing Remarks